The increase in price target by Piper Sandler from $78 to $104, while maintaining a Neutral rating, suggests a positive reassessment of Blueprint Medicines' valuation without changing the overall investment stance. This adjustment could lead to short-term positive sentiment among investors, potentially driving the stock price up as the new target suggests a higher valuation than previously estimated.